Peterson, Per A,Leturcq, Didier J.,Heiskala, Marja,Degraw, Juli,Jackson, Michael R.,Moriarty, Ann
申请号：
AU2008200524
公开号：
AU2008200524B2
申请日:
2008.02.05
申请国别(地区):
AU
年份:
2012
代理人:
摘要：
#$%^&*AU2008200524B220120112.pdf#####Abstract T cell responses are often diminished in humans with a compromised immune system. We have developed a method to isolate, stimulate and expand naive cytotoxic T 5 lymphocyte precursors (CTLp) to antigen-specific effectors, capable of lysing tumor cells in vivo. This ex vivo protocol produces fully functional effectors. Artificial antigen presenting cells (AAPCs Drosophila melanogaster) transfected with human HLA class I and defined accessory molecules, are used to stimulate CD8+ T cells from both normal donors and cancer patients. The class I molecules expressed to a high density on the 10 surface of the Drosophila cells are empty, allowing for efficient loading of multiple peptides that results in the generation of polyclonal responses recognizing tumor cells endogenously expressing the specific peptides. The responses generated are robust, antigen-specific and reproducible if the peptide epitope is a defined immunogen. This artificial antigen expression system can be adapted to treat most cancers is a significant 15 majority of the population.
